Preclinical characterisation of antibody-drug conjugates - ADME perspective
23 August 2021
Antibody drug conjugate (ADC) comprise of a monoclonal antibody and cytotoxic payload conjugated by a linker. The antibody is purposed to deliver the payload to the target located on the cancer cell. The payload is typically a highly potent small molecule, which should be released from the carrier antibody inside the tumour cell. The number of the released but differently conjugated small molecules is affected by the used conjugation method and strategy.Read more
A new e-book is out and it’s all about biologics!
1 June 2021
Admescope’s e-book series was launched in 2017 and the six e-books published over couple of years cover comprehensively ADME-tox topics for small molecules, the latest one being about Safety Metabolism in 2019. We have been delighted by the received positive feedback and huge interest towards our e-books.Read more
Glycoprofiling of antibodies – what, how and why?
15 October 2020
Proteins go through various post-translational modifications (PTM) while produced by the cells. Glycosylation is one of the most common PTM and it can have tremendous effects on the physicochemical properties, structure, and function of proteins. Failures in the physiological glycosylation process can lead to serious health conditions, which describes its importance. This blog post elucidates why it is crucial to know and characterise glycoprofile of glycoprotein-based biologics and how this can be done.Read more
Protein quantification with mass spectrometry
3 May 2019
The development of analytical techniques has enabled applying mass spectrometry methods also for protein quantification from biological samples. The use of LC/MS brings in more analytical potential due to its versatility and accuracy and hence, its importance as an analytical tool for protein characterisation is increasing. If not being familiar with the topic, it may be interesting to have a peek how proteins are quantified from biological matrixes with LC/MS.Read more
Biologics vs small molecule drugs – what’s the difference?
19 November 2018
Biologics-based drugs have been increasing their market share over the last decade and the number of companies working with biologics keeps on growing. Last year, 17 new biologics-based drugs were approved by FDA, being the highest yearly approved number of biologics so far. The advances in biotechnology and analytical techniques have facilitated the development in the field, and will most likely continue doing so in the future.Read more
